Lupin Limited received final approval from the United States Food and Drug Administration for its Abbreviated New Drug Application for Pitolisant Tablets in strengths of 4.45 mg and 17.8 mg. The approval designates the product as bioequivalent to the reference listed drug Wakix®, clearing the path for a US market launch of the generic version.

Approval details

The key parameters of the regulatory approval are as follows:

Regulatory context

The disclosure was made pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company issued the press release to the National Stock Exchange of India Limited and BSE Limited on August 17, 2026.

Portfolio implications

Pitolisant is used in the treatment of central nervous system disorders. By securing approval for these specific strengths, Lupin adds another branded-equivalent product to its US generics pipeline. The company operates 15 manufacturing sites and six research centers globally, supporting its focus on complex generics and specialty formulations across therapy areas including respiratory, cardiovascular, and central nervous system health.

Lupin Limited has published the transcript of its first-quarter fiscal year 2027 (Q1FY27) earnings conference call, providing detailed management commentary on its record financial performance and strategic outlook. The call, held on August 07, 2026, followed the release of unaudited results showing consolidated net sales of ₹8,277 crore, a 32% year-on-year increase, and adjusted EBITDA of ₹2,464 crore, up 50% year-on-year. This marks the company’s 16th consecutive quarter of revenue growth.

The disclosure was made pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The transcript is available on the company’s official website.

Financial Performance Recap

Management emphasized that the quarter set new benchmarks for the company. Consolidated net sales reached ₹8,277 crore, up from ₹6,194 crore in Q1FY26. Adjusted EBITDA (excluding forex and other income) jumped to ₹2,464 crore from ₹1,641 crore, with margins expanding by 340 basis points to 30% from 26.6%. Gross margins improved by 330 basis points to 74.6%, driven by better product mix, higher profitability in India, and cost efficiencies. Profit after tax (PAT) rose 16.1% to ₹14,150 crore, supported by operating leverage despite a higher effective tax rate of 29.8%.

Regional Insights and Strategy

The US business contributed significantly, with sales growing 43% year-on-year to USD 366 million. However, management cautioned that increased competition in key products like Mirabegron and Tolvaptan will impact US revenues in subsequent quarters. The company expects US quarterly revenues to moderate to between USD 250 million and USD 280 million over the next few quarters as new entrants gain share. Full-year US revenue guidance remains at USD 1.1 billion to USD 1.2 billion.

Ex-US markets demonstrated robust organic growth exceeding 20%. India’s prescription business grew 15.1% year-on-year to ₹2,380 crore, outperforming the industry prescription market (IPM) growth of 13.5%. Volume growth in India stood at 6.1%, with the chronic segment accounting for 67% of the portfolio. Other Developed Markets (ODM) surged 48% to ₹1,149 crore, aided by the consolidation of VISUfarma. Emerging markets grew 52% to ₹990 crore, led by a 117% local currency increase in Brazil.

Pipeline and Innovation

Lupin outlined an aggressive pipeline strategy, aiming to launch over 50 products in the US over the next three years, including 10 exclusive first-to-files and five biosimilars. Key upcoming launches include Pegfilgrastim and Dalbavancin injectable in FY27, and Apixaban 505(b)(2) in FY28. In India, the company targets novel proprietary products to contribute one-third of revenues within 10 years, supported by a pipeline of over 80 new product launches.

What the Numbers Show

The divergence between record top-line growth and management’s cautious near-term US guidance highlights a transition phase. While gross margins expanded to 74.6%, driven by operational efficiencies and mix shifts, the anticipated price erosion in high-revenue US molecules like Tolvaptan poses a risk to sustaining current EBITDA margins of 30%. The company’s full-year EBITDA margin guidance of around 25% reflects this expected moderation, contrasting sharply with the 30% achieved in Q1FY27. Additionally, the decline in other operating income from ₹105 crore to ₹60 crore, due to lower PLI export benefits, underscores the reliance on core operational performance rather than incidental gains.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE326A01037/8c28a687-2f7b-4228-b4e7-3320a1a59534.pdf